Loading…
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. The company was incorporated in 2017 and is headquartered in Carlsbad, California.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-79M | $-70M | $-55M | -32.8% | - | - |
| 2024 | $0M | $-62M | $-50M | $-43M | -20.5% | - | - |
| 2023 | $0M | $-78M | $-67M | $-59M | -24.1% | - | - |
| 2022 | $0M | $-67M | $-63M | $-52M | -19.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 67.59 | 78.19 | 62.38 | 79.47 |
| Operating Income | -67.59 | -78.19 | -62.38 | -79.47 |
| EBITDA | -67.19 | -77.65 | -61.79 | -78.84 |
| EBIT | -67.59 | -78.19 | -62.38 | -79.47 |
| Pretax Income | -63.31 | -66.86 | -49.59 | -69.79 |
| Net Income | -63.31 | -66.86 | -49.59 | -69.79 |
| Net Income Common Stockholders | -63.31 | -66.86 | -49.59 | -69.79 |
| Total Expenses | 67.59 | 78.19 | 62.38 | 79.47 |
| Interest Income | 0 | 11.33 | 12.79 | 9.68 |
| Research And Development | 48.61 | 57.06 | 44.35 | 59.13 |
| Selling General And Administration | 18.98 | 21.13 | 18.03 | 20.34 |
| Normalized EBITDA | -67.19 | -77.65 | -61.79 | -78.84 |
| Normalized Income | -63.31 | -66.86 | -49.59 | -69.79 |
| Basic EPS | -1.14 | -1.19 | -0.88 | 0 |
| Diluted EPS | -1.14 | -1.19 | -0.88 | 0 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -63.31 | -66.86 | -49.59 | -69.79 |
| Reconciled Depreciation | 0.41 | 0.54 | 0.60 | 0.62 |
| Net Interest Income | 0 | 11.33 | 12.79 | 9.68 |
| Net Income From Continuing And Discontinued Operation | -63.31 | -66.86 | -49.59 | -69.79 |
| Total Operating Income As Reported | -67.59 | -78.19 | -62.38 | -79.47 |
| Diluted Average Shares | 55.71 | 55.98 | 56.59 | 0 |
| Basic Average Shares | 55.71 | 55.98 | 56.59 | 0 |
| Diluted NI Availto Com Stockholders | -63.31 | -66.86 | -49.59 | -69.79 |
| Net Income Including Noncontrolling Interests | -63.31 | -66.86 | -49.59 | -69.79 |
| Net Income Continuous Operations | -63.31 | -66.86 | -49.59 | -69.79 |
| Other Income Expense | 4.29 | 11.33 | 0 | 0 |
| Other Non Operating Income Expenses | 4.29 | 11.33 | 0 | 0 |
| Net Non Operating Interest Income Expense | 0 | 11.33 | 12.79 | 9.68 |
| Interest Income Non Operating | 0 | 11.33 | 12.79 | 9.68 |
| General And Administrative Expense | 18.98 | 21.13 | 18.03 | 20.34 |
| Other Gand A | 18.98 | 21.13 | 18.03 | 20.34 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Design Therapeutics, Inc.this co. | DSGN | - | - | - | -32.8% | - |
| Actuate Therapeutics, Inc. Common stock | ACTU | $68M | - | 8.45 | -280.5% | - |
| LENSAR, Inc. | LNSR | $65M | - | -2.48 | 131.7% | -3.17 |
| Pulmonx Corporation | LUNG | $51M | - | 0.92 | -99.8% | -0.71 |
| Accuray Incorporated | ARAY | $50M | - |
| 0.94 |
| -2.0% |
| -107.66 |
| INmune Bio Inc. | INMB | $35M | - | 1.50 | -195.3% | -0.38 |
| Myomo, Inc. | MYO | $31M | - | 2.68 | -136.6% | -2.33 |
| Tvardi Therapeutics, Inc. | TVRD | $29M | - | 1.37 | -87.0% | 0.07 |
| Tevogen Bio Holdings Inc. | TVGN | $27M | - | -1.52 | 319.1% | -1.64 |
| Peer Median | - | - | 1.15 | -93.4% | -1.64 | |